
Stanford University researchers seem to have narrowed down upon the amino acid which could support resistant drugs to fight diseases.
The study authors slated to present their study later this week, will explain in detail the use of arginine in helping drugs outwit pumps in the membrane which have become resistant to the drug.
Advertisement
In their experiment on mice, scientists employed eight arginine molecules to envelop Taxol, a chemotherapeutic agent, to effectively target the Taxol-immune ovarian cancer cells.
Paul Wender, professor of chemistry at Stanford University, and one of the authors of the study said, "If we think of the pump as being a bouncer for the cellular club, then affectively what we're doing is disguising one of these therapeutic agents to get it in through the back door or side door. We're not even going to deal with the bouncer."
Even though Taxol was employed for the study, researchers were extremely hopeful of arginines' use with other drugs like antibiotics.
"This could potentially be used with any drug which is effective but has a delivery problem," said co-author Nelson Teng, professor of obstetrics and gynecology.
Source: Medindia
SAV/S
Advertisement
Even though Taxol was employed for the study, researchers were extremely hopeful of arginines' use with other drugs like antibiotics.
"This could potentially be used with any drug which is effective but has a delivery problem," said co-author Nelson Teng, professor of obstetrics and gynecology.
Source: Medindia
SAV/S
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Drug News

Researchers create needle-free Zika vaccine patch, using HD-MAP tech, aiming to protect against fatal virus spread by mosquitoes.

Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.

The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.

The most significant decrease in autoimmune thyroid disease risk was observed in rheumatoid arthritis patients receiving immunomodulatory drugs or 'biological DMARDs'.

Human apotransferrin injected to mice models suffering from intracerebral hemorrhage was found to mitigate the serious effects of stroke.